You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Foundayo ™ (orforglipron) tablet
0.8 mg / 2.5 mg / 5.5 mg / 9 mg / 14.5 mg / 17.2 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Foundayo™ (orforglipron) be used in nursing women?
Orforglipron is not recommended for nursing women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for orforglipron and any potential adverse effects on the breastfed child.
See important safety information, including boxed warning, in the attached prescribing information.
Orforglipron Use in Lactation
Risk Summary
There are no data on the presence of orforglipron or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.1
Orforglipron was present in the milk of lactating rats in in vivo testing. When a drug is present in animal milk, it is likely that the drug will be present in human milk.1
Orforglipron is not recommended for nursing women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for orforglipron and any potential adverse effects on the breastfed child from orforglipron or from the underlying maternal condition.1
Animal Data
In a tissue distribution study, [14C]orforglipron-derived radioactivity was excreted into rat breast milk, with concentrations in milk 3-fold higher than in plasma.1
Enclosed Prescribing Information
References
1Foundayo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
Date of Last Review: September 16, 2026